dc.creator | Vázquez Montero, Lucía | es |
dc.creator | Álamo de la Gala, María del Carmen | es |
dc.creator | Cruz Merino, Luis de la | es |
dc.date.accessioned | 2024-03-01T18:28:10Z | |
dc.date.available | 2024-03-01T18:28:10Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Vázquez Montero, L., Álamo de la Gala, M.d.C. y Cruz Merino, L.d.l. (2023). Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations. Frontiers in Oncology, 13, 01-09. https://doi.org/10.3389/fonc.2023.1187840. | |
dc.identifier.issn | 2234-943X | es |
dc.identifier.uri | https://hdl.handle.net/11441/155768 | |
dc.description.abstract | The development of immune checkpoint inhibitors has revolutionized the
landscape of treatment of advanced melanoma in recent years. Based on the
efficacy results of the phase III CheckMate 067 trial, nivolumab in combination
with ipilimumab is one of the first-line standard options for advanced melanoma
along with pembrolizumab, nivolumab, and, recently, nivolumab plus relatlimab.
Counterbalancing its efficacy, nivolumab plus ipilimumab is associated with
severe immune-related toxicity. This article will review the efficacy and safety
of the nivolumab plus ipilimumab combination in advanced melanoma across
phase I, II, and III clinical trials that evaluated this approach. We also explore the
benefit of the combination schedule across different subgroups of patients and
possible predictive biomarkers for efficacy outcomes in order to elucidate which
patients could be the best candidates for combination or single-agent therapy.
Patients with BRAF-mutant tumours, asymptomatic brain metastases, or PD-L1-
negative status appear to reach better survival outcomes with the combination
relative to single-agent immunotherapy. | es |
dc.format | application/pdf | es |
dc.format.extent | 9 p. | es |
dc.language.iso | eng | es |
dc.publisher | Frontiers Media S.A. | es |
dc.relation.ispartof | Frontiers in Oncology, 13, 01-09. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Nivolumab | es |
dc.subject | Ipilimumab | es |
dc.subject | Advanced melanoma | es |
dc.subject | Safety | es |
dc.subject | Efficacy | es |
dc.title | Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1187840/full | es |
dc.identifier.doi | 10.3389/fonc.2023.1187840 | es |
dc.contributor.group | Universidad de Sevilla. CTS151: Bioquímica médica. | es |
dc.journaltitle | Frontiers in Oncology | es |
dc.publication.volumen | 13 | es |
dc.publication.initialPage | 01 | es |
dc.publication.endPage | 09 | es |